Victor Fabano
Chief Operating Officer bei OSPY MEDI CDI
Profil
Victor Fabano is currently working as the Vice President of Operations & Information Technology at Osprey Medical, Inc. He started this position in 2018.
Prior to his current role, he worked as the Vice President of Operations & Quality at Anulex Technologies, Inc. from 2008 to 2012.
Mr. Fabano completed his undergraduate degree at the University of North Dakota.
Aktive Positionen von Victor Fabano
Unternehmen | Position | Beginn |
---|---|---|
OSPY MEDI CDI | Chief Operating Officer | 01.06.2012 |
Ehemalige bekannte Positionen von Victor Fabano
Unternehmen | Position | Ende |
---|---|---|
Anulex Technologies, Inc.
Anulex Technologies, Inc. Medical SpecialtiesHealth Technology Anulex Technologies, Inc. develops medical technologies. It focuses on the research and development of medical technologies to preserve and repair soft tissue of the spine for patients undergoing a surgical procedure to remove a herniated disc. The company was founded in 2001 by Matthew M. Burns and is headquartered in Minneapolis, MN. | Chief Operating Officer | 01.01.2012 |
Ausbildung von Victor Fabano
University of North Dakota | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Anulex Technologies, Inc.
Anulex Technologies, Inc. Medical SpecialtiesHealth Technology Anulex Technologies, Inc. develops medical technologies. It focuses on the research and development of medical technologies to preserve and repair soft tissue of the spine for patients undergoing a surgical procedure to remove a herniated disc. The company was founded in 2001 by Matthew M. Burns and is headquartered in Minneapolis, MN. | Health Technology |
Osprey Medical, Inc.
Osprey Medical, Inc. Medical SpecialtiesHealth Technology Osprey Medical, Inc. engages in the development to prevent harmful effect of x-ray dye used during angiographic imaging procedures. Its product includes Dyevert system, which is designed to reduce the amount of dye contrast injected into the patients during standard cardiovascular procedures. The company was founded by Frank Solomon, David Kaye, and James Edward Shapland on August 31, 2005 and is headquartered in Minnetonka, MN. | Health Technology |